西班牙的老年病学和人工智能 (Ger-IA项目):与ChatGPT交谈,这是一个全国性的调查
Daniel Rosselló-Jiménez1, S Docampo2, Y Collado3
1Geriatric Medicine Department, Hospital Universitari de Terrassa, Consorci Sanitari de Terrassa, Carr. Torrebonica, s/n, Terrassa, 08227, Barcelona, Spain. rossello.daniel@gmail.com.
European geriatric medicine
|April 14, 2024
概括
老年医生发现,人工智能 (AI) 工具ChatGPT的表现有变化,在理论问题上得分更高,但在复杂决策和诊断方面得分更低. 人工智能看起来很有前途,但在临床实践中存在局限性.
科学领域:
- 老年医学 老年医学
- 医疗保健中的人工智能
- 临床决策支持系统 临床决策支持系统
背景情况:
- 人工智能 (AI) 在医疗实践中的整合正在迅速推进.
- 在专业医疗领域评估像ChatGPT这样的AI工具的性能至关重要.
- 了解医生同意人工智能生成的医疗信息对于安全实施至关重要.
研究的目的:
- 评估老年医生与ChatGPT在各种老年医疗领域的反应之间的协议.
- 为了比较老年专家和住院医生之间关于ChatGPT答案的一致程度.
- 分析聊天GPT在老年病的不同知识领域的表现.
主要方法:
- 一项观察性研究涉及来自西班牙41个部门的126名老年医生.
- 对ChatGPT提出了十个与老年病相关的问题;医生根据利克特尺度对答案进行了评估.
- 数据分析包括计算ChatGPT在五个知识领域的答案的平均得分和标准偏差.
主要成果:
- 聊天GPT的平均得分为3.1/5,跨知识领域的差异很大.
- 与居民 (3.3/5) 相比,专家对ChatGPT (3.0/5) 的同意程度较低 (P < 0.05).
- 聊天GPT在一般/理论问题上表现最好 (M: 3.96),在复杂决策/生命终点 (M: 2.50) 和诊断测试 (M: 2.48) 上表现最差.
结论:
- 聊天GPT在老年病的表现高度依赖于领域,在理论领域表现出色,但在复杂的临床场景中扎.
- 人工智能在关键决策,治疗适当性和诊断测试解释方面存在重大局限性.
- 虽然人工智能已准备好进行整合,但其当前的能力受到限制,特别是在细微的医疗决策方面.
更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.5K
11:21Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data
Published on: July 27, 2018
8.2K
相关概念视频
Aging
49
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
49
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
